

Principles and Practice of Endocrinology and Metabolism, Second Edition, edited by Kenneth L. Becker. J. B. Lippincott Company, Philadelphia, © 1995.

CHAPTER 216

SEX HORMONES AND HUMAN CARCINOGENESIS: EPIDEMIOLOGY

ROBERT N. HOOVER

Because of the central role that the hormonal milieu plays in various carcinogenic processes, it is essential that clinical endocrinologists be aware of malignancies to which their patients may be predisposed, either because of the nature of their illness or because of the nature of the hormonal therapy being instituted.

CARCINOGENESIS AND ENDOGENOUS SEX HORMONE STATUS

Endogenous hormone status has long been thought to be an important factor in the etiology of a number of human malignancies, and this belief has been based on animal carcinogenesis studies (see Chap. 215), the responsiveness of a number of tumors to hormonal manipulation (see Chaps. 217 and 218), the relationship of risk of certain tumors to a variety of reproductive and other factors thought to influence hormonal status, and the simple fact that some organs depend on hormonal status for their normal function.¹ Speculation about a hormonal cause has focused on malignancies of the female breast and the reproductive tract. However, some evidence for hormonal carcinogenesis has been observed for a variety of other tumors, including prostate, testis, thyroid, and gallbladder cancers, and malignant melanoma. Despite these long-standing suspicions, with the possible exception of endometrial cancer, there has been little success in identifying the specific hormonal factors that might be responsible for these tumors.

CARCINOGENESIS AND EXOGENOUS SEX HORMONE THERAPY

Within the last 40 years, a new element in the area of hormonal influences on cancer risks has been added, that of exogenous sex hormone exposure. Pharmacologic levels of estrogens, progestins, androgens, and pituitary trophic hormones, alone or in combination, have been administered to large segments of the population for various reasons. These large-scale "natural experiments" have provided more specific insights into the relationship between hormonal factors and several different malignan-

cies.² Moreover, enthusiasm has grown for the widespread treatment of relatively healthy segments of the population (e.g., oral contraception, menopausal replacement therapy). There is considerable interest in the use of estrogens for postmenopausal prevention of osteoporosis and osteoporotic fractures³ (see Chaps. 63 and 97). Some evidence supports the long-suspected potential of menopausal estrogens to prevent clinical coronary heart disease.⁴ Because of this enthusiasm, appropriate evaluations of the carcinogenic consequences of these exposures has become important to public health, as well as to understanding the biology of the tumors involved.

ENDOMETRIAL CANCER

ENDOGENOUS FACTORS IN ENDOMETRIAL CANCER

The cancer for which the evidence for both an endogenous and an exogenous hormonal cause is best established is endometrial cancer.

Various factors related to endogenous hormone production have been associated with endometrial cancer.⁵ Medical conditions related to increased risk include functional (estrogen-secreting) ovarian tumors, the polycystic ovary syndrome, diabetes mellitus, and hypertension. Reproductive factors also have consistently been found to be related to increased risk, including nulliparity and a late natural menopause. Some dietary factors also seem to influence risk, including obesity as a risk factor and vegetarian diet as a possible protective factor.⁶ Age, a determinant of levels of most endogenous hormones, also influences endometrial cancer risk in a unique manner. Endometrial cancer rates are extremely low in women younger than 45 years of age, rise precipitously among women in their late 40s and throughout their 50s (much more dramatically than for other tumors), and then decline from about age 60 years and older (Fig. 216-1).

EXOGENOUS SEX HORMONES AND ENDOMETRIAL CANCER

Exogenous hormones also have been linked to endometrial cancer.⁷




FIGURE 216-1. Age-specific incidence rates for breast and uterine corpus cancers among white women during 1986 through 1990. (Data from the Surveillance, Epidemiology and End Results Program. Adapted from DeVesa SS. Cancer patterns among women in the United States. *Semin Oncol Nurs.* in press.)

ESTROGENS AND ENDOMETRIAL CANCER

Estrogen replacement therapy of the menopause for 2 years or longer is associated with an excess relative risk (RR) of endometrial cancer. Table 216-1 shows estimated RRs (i.e., the risk of the disease among those exposed to estrogen therapy compared with the risk among those not exposed).⁸⁻¹⁵ The RR among users compared with nonusers ranges from twofold to eightfold. It increases even further with long duration of use and with high average daily doses. Thus far, every type of estrogen that has been investigated has shown this relationship, including conjugated equine estrogens, ethinyl estradiol, and diethylstilbestrol (DES). The highest risk occurs among current users. The risk declines with each year after cessation of use, although apparently there is some residual excess risk even 10 years after cessation. The risk is highest for early stage malignancies, but there is a twofold to threefold excess risk for the advanced stages of disease as well. (After early positive studies, some investigators questioned whether the association might be spurious because of the opportunities for enhanced detection of latent endometrial cancer among estrogen users. Various approaches yielded evidence consistent with a causal relationship between menopausal estrogen treatment and an increased risk of endometrial cancer.)

EFFECT OF ESTROGEN-PROGESTERONE IN SEQUENCE

There has been a profound trend away from unopposed estrogen treatment of menopausal symptoms and toward treatment with a sequence of an estrogen, which is then combined with a progestin. Substantial evidence¹⁶ supports that such cyclic treatment reduces the frequency of hyperplasia and atypical hyperplasia associated with unopposed estrogen treatment. The first epidemiologic data on risk of endometrial cancer itself has appeared. Although based on small numbers of observations, use of the combined regimen is related to substantially lower risks than those associated with the estrogen-only regimen. Nevertheless, whether exclusive use of the combined regimen is related to any excess risk remains unclear. However, it is certain that such use does not prevent the background or "expected" numbers of cancers, nor does it remove the excess risk induced by any prior use of the estrogen-only regimen.¹⁵⁻¹⁸

ORAL CONTRACEPTIVES AND ENDOMETRIAL CANCER

Oral contraceptives also have been studied extensively in relation to endometrial cancer, after the observations in the early 1970s that young women receiving sequential oral contraceptives (particularly dimethisterone and ethinyl estradiol [Oracon]) were developing endometrial cancer.¹⁹ Subsequent investigations esti-

TABLE 216-2
Relative Risks* of Endometrial Cancer Associated With Combination Oral Contraceptive Use From Five Case-Control Studies

Reference	Source of Controls	Overall RR	RR Among Long-Term Users†
Weiss and Sayvetz ²⁰	Community	0.5	
Kaufman et al. ²¹	Hospital patients	0.5	0.3
Hulka et al. ²²	Community	0.4	0.3
Stanford et al. ²³	Community	0.4	0.2
CDC ²⁴	Community	0.5	0.6

* Risk of cancer relative to a risk of 1.0 for women who never used oral contraceptives.
† Definition of long-term varied from ≥ 4 to ≥ 10 years.
CDC, Centers for Disease Control; RR, relative risks.

ated that such women were at a twofold to eightfold excess risk of this tumor. On the other hand, nonsequential, combination oral contraceptives clearly are related to decreased risks of endometrial cancer (Table 216-2). RRs of 0.4 to 0.5 have been observed, indicating a 50% to 60% protection associated with such use.¹⁸⁻²⁵ There is also some evidence of increased levels of protection with increased years of use. The effects of stopping use are unclear. Three studies^{22,24,25} have noted that the protection was substantial among current users and subsided after cessation. These studies, however, disagreed on the duration of protection after stopping. In addition, most studies have observed profound interaction between other endometrial cancer risk factors and the associations with combination oral contraceptive use. Specifically, the protective effect is attenuated among the obese,¹⁶ among long-term estrogen users,²⁵ and among the multiparous. Although the same interactions have not been found in all studies, these observations are consistent with a number of these risk factors operating through common or highly correlated hormonal mechanisms.

MECHANISMS OF ACTION

A unified theory²⁷ of how these risk factors operate has been proposed (Fig. 216-2). Most known risk factors are associated with increased levels of circulating estrogens, particularly estrogens not bound to protein. Clearly, also related are the age effects, and the use of combination oral contraceptives, which probably modify the increased risk associated with estrogen level through the modulating effects of progestogens. Furthermore, although nulliparity, diabetes, hypertension, and race have not yet been included in this scheme, they possibly will be as our knowledge of basic endocrinology expands.

The model suggests several promising lines of future clinical, epidemiologic, and laboratory research. The way that obesity affects the peripheral conversion of estrogen precursors deserves more attention. When in a woman's life does obesity matter most? Some data suggest that weight loss decreases circulating estrogens; other data do not. Does the number of adipocytes or their content determine peripheral conversion? What accounts for the reduced risk among vegetarians? The effects of progesterone also deserve further study, including resolving whether the protection given by combination oral contraceptives is transient, and measuring the effects of the new combination-type menopausal estrogen regimen.

Perhaps most important to our understanding of carcinogenesis will be the clarification of the precise mechanism by which circulating estrogens produce endometrial cancer. Several possibilities have been proposed: that estrogens are complete carcinogens themselves; that they promote initiated cells; or that they simply stimulate growth and, thereby, offer a greater opportunity for abnormal cells to arise or for carcinogens to act on vul-

TABLE 216-1
Relative Risks* of Endometrial Cancer Associated With Menopausal Estrogen Use From Selected Case-Control Studies

Reference	Source of Controls	Overall RR	RR Among Long-Term Users†
Ziel and Finkel ⁸	Health plan	7.6	13.9
Mack et al. ⁹	Retirement community	5.6	8.8
Gray ¹⁰	Private practice	3.1	11.6
Antunes et al. ¹¹	Hospital patients	4.3	15.0
Weiss et al.‡ ¹²	Community	7.9	14.3
Hulka et al. ¹³	Gynecology patients	1.8	4.1
Shapiro et al. ¹⁴	Hospital patients	3.9	6.0
Brinton et al. ¹⁵	Community	3.0	6.0

* Risk of cancer relative to a risk of 1.0 for women who never used menopausal estrogens.
† Definition of long-term varied from ≥ 5 to ≥ 10 years.
‡ Refers to continuous users.
RR, relative risks.




FIGURE 216-2. Risk Factors for endometrial cancer and their possible modes of action. (From Brinton LA, Hoover RN. *Epidemiology of gynecologic cancers*. In: Hoskins WJ, Perez CA, Young RC, eds. *Principles and practice of gynecologic oncology*. Philadelphia: JB Lippincott, 1992:3.)

nerable genetic material. The epidemiologic evidence strongly favors the argument that estrogens act at a relatively late stage in the process of carcinogenesis. If estrogens are promoters, however, no initiators of the process are readily apparent.

BREAST CANCER

The hormonal etiology of breast cancer is well accepted, but no unified model for the mechanism exists. Several hormonal hypotheses have been suggested, but supporting data are lacking.

ENDOGENOUS FACTORS IN BREAST CANCER

The importance of the ovary in breast cancer etiology is demonstrated by its relationship to a number of breast cancer risk factors.²⁸ Earlier ages at menarche are associated with high risks of breast cancer. Similarly, later ages at natural menopause also are associated with elevated risks. Surgical removal of the ovaries before natural menopause reduces risk of breast cancer, and the earlier the operation, the lower the risk. The shape of the age-incidence curve for this disease (see Fig. 216-1) has been interpreted as showing that the onset of ovarian activity early in life determines the slope of the curve, and that a reduction in this ovarian factor around the time of the menopause is responsible for the change in slope of the curve at about 50 years of age.

Other risk factors for breast cancer also have been well established.²⁹ A history of breast cancer in a first-degree relative elevates a woman's risk of contracting breast cancer twofold to fivefold. Historical observations of a protection against breast cancer associated with an increase in parity were found to reflect the influence of the age at first birth. A woman who has her first child after the age of 30 years has approximately twofold to threefold the risk of breast cancer of a woman who had her first child when younger than 18 years of age. Nulliparous women have approximately the same risk as those women who had their first child at 30 years of age, whereas women having a first birth after this age actually experience a greater risk than do nulliparous women. Investigations³⁰ have implied that increased parity may indeed diminish the risk of breast cancer, even when controlled for age at first birth. Benign breast disease, particularly that containing hyperplastic or dysplastic elements, places a

woman at a twofold to fivefold excess risk of subsequent breast cancer.³¹ Body size also relates to breast cancer risk. Height or frame size is positively associated with risk. Obesity, or an increasing body mass index, is associated with an increase in breast cancer risk among menopausal women, although the magnitude of the increase in RR is much less than that for endometrial cancer. Evidence indicates that obesity is associated with a decreased breast cancer risk among premenopausal women.³²

INFLUENCE OF DIET

Diet is strongly suspected of playing a role, because of worldwide differences in breast cancer rates. Oriental populations have rates fivefold to sixfold lower than those seen in the United States and Western Europe. Migrants from Japan and China to the United States experience risks that rise toward the levels of whites over the course of two generations of residence within the United States. Whereas some direct support³³ for these dietary hypotheses has been proposed, a number of studies³⁴⁻³⁷ have found no relationship, and the entire area remains controversial.

HYPOTHESES FOR THE CAUSATION OF BREAST CANCER

It frequently is speculated that a unifying hormonal hypothesis for breast cancer is possible, because even the nonovarian risk factors actually may operate through a hormonal mechanism. Perhaps the simplest of these models^{38,39} is that breast cancer risk reflects total lifetime, or perhaps early life, dose of estrogens. Related to this is the unopposed-estrogen hypothesis,⁴⁰ which also assumes that estrogens are the important risk factor, but emphasizes the relative protective role of progesterone. The estrogen-fraction hypothesis⁴¹ also assumes estrogens to be hazardous, but adds that a woman's risk reflects the proportions of different estrogens, because they have different carcinogenic potentials. The estrogen-window hypothesis⁴² suggests that in a relatively short period after menarche, and then again in another short period before menopause, estrogen exposure, unopposed by progesterone, might cause an enhanced susceptibility to other carcinogenic influences on breast tissue. Another hypothesis⁴³ holds that the proportion of free versus protein-bound estrogen determines a woman's breast cancer and endometrial cancer risk.

Finally, pituitary hormones and prolactin in particular have been suggested as being primarily involved in breast carcinogenesis.⁴⁴

Confirmation for these hypotheses has been sought by measuring levels of various hormones: first, in breast cancer patients and controls either at the time of diagnosis or at some time before; and second, in women with different levels of known risk factors, to determine whether the risk factors operate through specific hormones. These laboratory-epidemiologic studies do not rule out any of the proposed models of endogenous hormone effects as a partial explanation, nor do they support any one model as the unified explanation, perhaps because the women are being tested at ages other than those critical for breast cancer risk modification. Or, perhaps, the premise of a unifying hypothesis is incorrect.

Thus, although the evidence that breast cancer is a tumor of hormonal etiology is overwhelming, the specific endogenous hormones involved and their relative roles remain elusive.

EXOGENOUS SEX HORMONES AND BREAST CANCER

The role of exogenous hormones is even less defined. In particular, it is not clear whether the use of estrogens postmenopausally or of oral contraceptives affects breast cancer risk.

ESTROGENS AND BREAST CANCER

The widespread use of noncontraceptive estrogens seems to be an ideal natural experiment through which to evaluate some of the more prominent hormonal hypotheses about breast cancer etiology. Unfortunately, the relationship remains controversial because of conflicting evidence. A retrospective cohort study⁴⁵ reported in 1976 suggested a relatively small overall excess risk (30%) among conjugated estrogen users, which reflected a twofold excess risk among long-term users. Over the ensuing decade, seven case-control studies and one follow-up investigation⁴⁶⁻⁵³ without significant methodologic flaws addressed this observation (Table 216-3). Three of the case-control studies³⁶⁻⁴⁸ had positive results, with evidence of dose response and an excess risk of up to twofold among long-term users. Two studies^{49,50} show some evidence of an association, but also contain some inconsistencies in dose-response relationships or subgroup analyses. Two studies^{51,52} clearly gave negative results, with no evidence of association with long-term use. The two negative-result studies are the only two that used a hospital comparison group, rather than the general population. If hospitalized women more commonly used replacement estrogens than women in the general community, these studies would underestimate any increase in risk.

TABLE 216-3
Relative Risk* of Breast Cancer Associated With Menopausal Estrogen Use From Seven Case-Control Studies

Reference	Source of Controls	Overall RR	RR Among Long-Term Users†
Ross et al. ⁴⁶	Community	1.1	1.9
Hoover et al. ⁴⁷	Health plan	1.4	1.7
Brinton et al. ⁴⁸	Mammography screening program	1.0	1.5
Hulka et al. ⁴⁹	Hospital patients	1.5	0.7
	Community	1.6	1.7
Hiatt et al. ⁵⁰	Health plan	0.7	2.8
Kelsey et al. ⁵¹	Hospital patients	1.0	0.7
Kaufman et al. ⁵²	Hospital patients	0.9	0.7

* Same as Table 216-1.

† Various definitions of long-term.

‡ Study limited to women having undergone bilateral oophorectomy.

RR, relative risks

Some studies have suggested that the association may be stronger among older women, those having undergone an oophorectomy, or those with a family history of breast cancer. However, these subgroup findings have not been consistent. Perhaps the most consistent finding is an enhanced excess risk associated with estrogen use among women with surgically confirmed benign breast disease. These findings have emerged from several of the case-control studies and refer to the entire population in the foregoing follow-up study.⁵³ Other studies⁵⁴⁻⁵⁷ have continued to produce conflicting evidence. Several metaanalyses of this accumulating body of evidence have been performed. When all of the data are considered, and the quality of the investigations taken into account, a more consistent pattern emerges of a dose- and duration-related increase in breast cancer risk, rising to a 60% excess for use of 15 or more years of menopausal estrogens.⁵⁷

As for endometrial cancer, the issue of what impact the use of the combined estrogen-cyclic progestin regimen will have on breast cancer has become a major research focus. The first study⁵⁶ to evaluate this issue found that in contrast to the pattern for endometrial cancer, the excess risk associated with estrogen replacement was not reduced in those also receiving cyclic progestins. In fact, the risk was higher and appeared earlier in these women than in those receiving the estrogen-only regimen.

Noncontraceptive hormonal exposures, other than the use of menopausal estrogen, are relatively rare and generally have not been investigated. A notable exception is the risk of breast cancer among women who took DES during a pregnancy to prevent a spontaneous abortion. Three clinical trials of DES use have been evaluated for long-term sequelae, and three follow-up studies of exposed women have also been reported.⁵⁸ Two of the three clinical trials showed evidence of excess breast cancer risk. Two of the cohort studies revealed overall excesses of 50%, with evidence of increasing risk with increasing interval from exposure, rising to 70% after 15 years of follow-up and 2.5-fold after 30 years.

Although considerable controversy remains concerning causality, practically, it seems prudent to assume that high cumulative doses of noncontraceptive estrogens are related to a 50% to twofold excess breast cancer risk after an interval of about 15 years since first exposure, and risk-benefit decisions about drug use should be made on this assumption.

ORAL CONTRACEPTIVES AND BREAST CANCER

The extensive use of oral contraceptives (see Chaps. 101 and 102) since they were licensed for use in the United States also seems to be a promising natural experiment, as well as an important public health issue. Overall, the results of such studies have been much more consistent than those for menopausal estrogen use, although these results are somewhat surprising. Because oral contraceptives so clearly alter the hormonal milieu, most investigators had predicted that oral contraception, particularly of long duration, would have a substantial impact on subsequent breast cancer risk. Whether this effect would be hazardous or beneficial was hotly debated. However, most studies have found essentially no relationship between the use of oral contraceptives and the risk of breast cancer either overall or among long-term users.

Oral Contraceptives in the Older Woman. There are two notable exceptions to the overall absence of effect. First, women who use oral contraceptives at older ages (40s and early 50s) appear to have an excess risk. Contraceptives used at these ages counter the natural decline in endogenous hormones and often cause an extension of menstrual activity, so the excess risks are like those seen with a later natural menopause. Because of the cardiovascular complications of oral contraceptive use, prominent among users older than 40 years of age, these medications are seldom used in this manner; thus, the effect may only be of historical interest.

Oral Contraceptives Used Extensively at an Early Age. The second exception to the overall absence of effect is among

women who use oral contraceptives extensively either at a young age or before having their first child. In the early 1980s, three studies⁵⁹⁻⁶¹ suggested an excess risk associated with such a pattern of use. Prompted by these concerns, a series of studies focused on breast cancer in young women were developed. Whereas not all studies are in accord, most of those that were sufficiently large and had enough long-term users for appropriate evaluations have confirmed these concerns. Three published studies⁶²⁻⁶⁴ and one unpublished study (Brinton LA, 1994), summarized in Table 216-4, have found remarkably similar results of around a doubling of breast cancer risk among long-term oral contraceptive users younger than 35 years of age. Some excess risk among such long-term users appears to persist in women up to age 40 or 45 years, but has not been observed among women developing breast cancer beyond these ages. What this means biologically with respect to carcinogenesis is unclear and controversial. However, what does seem clear from a practical standpoint is that extensive oral contraceptive use among young women is related to excess breast cancer among these women while they are still young.

Oral Contraceptives and Benign Breast Disease. A number of studies have noted significant protection against benign breast disease with oral contraceptive use. The protection is limited to current or recent use, with the effect disappearing 1 to 2 years after cessation. The magnitude of the protective effect also seems directly related to the dose of the progestin in the medication. Conflicting evidence exists on whether the effect applies to the pathologic subtypes of benign breast disease that are risk factors for the subsequent development of breast cancer. Because of the transitory nature of the protective effect and questions about the pathology involved, the biologic relevance of this association to breast cancer risk remains unclear.

FUTURE IMPERATIVES

Clearly the long-term consequences of oral contraceptive use on breast cancer risk will remain a research subject for many years. Only now are substantial numbers of women who used oral contraceptives for 5 or more years early in their reproductive lives entering the ages of high breast cancer risk. If the timing of the mammary effects of oral contraceptives resembles that of the endogenous hormonal risk factors and of exogenous estrogens, effects not detected before may become apparent. Moreover, if the age at exposure or the presence of other breast cancer risk factors (e.g., family history) modify the effect of contraceptive use, only large-scale and long-term efforts will yield precise estimates of these interactive effects. There is little question that such effects are of major public health importance because of widespread exposure to these compounds. Thus, although the data from a variety of studies are encouraging, the final conclusion on long-term sequelae of oral contraceptive use must be postponed.

The advent of enthusiasm for cyclic estrogen-progestogen treatment of the menopause offers the opportunity to investigate an exposure of particular relevance to a number of the etiologic theories concerning the hormonal basis of breast cancer. Such studies also seem to warrant a high priority, both on this basis and by virtue of the sudden onset of treatment of a large population of healthy women with this essentially unstudied drug combination therapy.

OVARIAN CANCER

Compared with cancers of the endometrium and breast, much less is known about risk factors for ovarian cancer. Until the late 1970s, it was little studied, but several extensive epidemiologic investigations have been undertaken.

INFLUENCING FACTORS IN OVARIAN CANCER

Only a few risk factors for ovarian cancer have been identified from these investigations, and they account for only a small

proportion of the disease, but the few factors consistently identified clearly imply a hormonal etiology for this malignancy.⁶⁵ First of all, parity is protective, with the risk of the disease being highest among nulliparous and declining by 70% among those with three or more live births. Independent of nulliparity, there is a consistent finding of a threefold to fivefold excess risk among women who have had medical consultation for infertility. Few other risk factors reflecting endogenous hormonal status have been identified for ovarian cancer, and none with any consistency among studies.

EXOGENOUS ESTROGENS AND OVARIAN CANCER

Exogenous estrogens have been studied in various case-control and follow-up studies over the last 7 years. Most studies have found no consistent association between menopausal estrogen use and the risk of ovarian cancer. The overall RRs in these studies have been close to 1.0 and yielded no evidence of higher risks for longer durations or higher doses of estrogen. One investigation⁶⁶ found an increased risk of ovarian cancer among women who received both conjugated estrogens and DES for the treatment of menopausal symptoms. However, the numbers of cases in this study were limited and the finding has not been confirmed.

ORAL CONTRACEPTIVES AND OVARIAN CANCER

Oral contraceptives, by contrast, appear to exert a marked protective effect. The effect seems to be related to duration, with those using oral contraceptives for more than 5 years having an approximately 50% to 70% reduced risk of the disease.⁶⁷

The encouraging nature of this result has overshadowed some inconsistencies among individual studies. Whether these differences reflect chance biases in some studies, the influences of varying patterns of use between studies, or meaningful biologic interactions remains unclear. Critical comparisons of the existing studies and new data may enhance our understanding of ovarian carcinogenesis and clarify risk-benefit issues, particularly as demographic patterns of oral contraceptive use continue to change. In particular, the influence of cessation of use on risk for ovarian cancer could use more study.

Possible Mechanism of Protection. The increased risk associated with infertility coupled with the decreased risk associated with increased parity and the extended use of the oral contraceptives implicates gonadotropin stimulation of the ovary in its carcinogenesis. Decreased stimulation should reduce the risk, and those conditions associated with enhanced stimulation should elevate the risk. If this unifying hypothesis is supported by further evidence, it would have direct implications on the consequences of several trends in endocrine therapy.

TABLE 216-4
Relative Risk of Breast Cancer in Women Younger Than 35 Years of Age Associated With Oral Contraceptive Use

Reference	Source of Controls	Overall RR	RR Among Long-Term Users*
U.K. Natl Case-Control ⁶⁴	General Practice Rolls	1.3	1.7
Paul et al. ⁶²	Community	1.2	2.2
White et al. ⁶³	Community	1.1	1.7
Brinton†	Community	1.3	2.3

* >8 years for U.K. study, ≥10 years for the others.
† Brinton LA, 1994.
Natl, National; RR, relative risks; U.K., United Kingdom.

CANCER OF THE UTERINE CERVIX

RISK FACTORS AND CERVICAL CANCER

Most findings from studies⁶⁸ of cervical cancer are consistent with a venereally transmitted agent being primarily involved. The two major risk factors that elevate a woman's risk of this malignancy are a large number of different sexual partners and an early age at first intercourse. In addition, among women with only one sexual partner, the more sexual partners her mate has had, the higher her risk of cervical cancer. Clinical, laboratory, and epidemiologic work on papilloma viruses suggests that these agents may be the key infectious factor in the etiology of this disease.⁶⁹

The strength of sexual, social, and specific infectious risk factors have tended to obscure other factors that might contribute to this disease. For example, it has been observed that cigarette smoking is a risk factor, even after control for sexual variables.⁷⁰ The presence of tobacco metabolites in cervical mucus provides a plausible biologic rationale for the role of tobacco.

ORAL CONTRACEPTIVES AND CERVICAL CANCER

Potential hormonal risk factors for cervical cancer have not been systematically sought, but the cervix is a target organ for several of the sex hormones and, therefore, a likely candidate for the modification of tumor incidence by hormonal factors. Studies⁷¹ linking increased risk to multiparity after appropriate control for sexual and viral risk factors support this notion. In addition, several case-control and follow-up studies have linked oral contraceptive use to cervical neoplasia. Whereas there was some concern that this association might be spurious, simply reflecting the related effects of the sexual and social-class risk factors for this disease, studies^{72,73} controlling for these effects have supported the likelihood of an association. Indeed, studies^{74,75} have continued to find excess risk for long-term oral contraceptive users even after control for papillomavirus infection. The higher risk associated with oral contraceptive use among the papillomavirus positive cases has led to speculation that hormonal factors in general, and oral contraception in particular, may be important cofactors in the carcinogenicity of papillomavirus infection.

IN UTERO DIETHYLSTILBESTROL EXPOSURE AND CERVICAL CANCER

A systematic follow-up of women who were exposed in utero to DES has revealed an increased incidence of cervical intraepithelial neoplasia among these women compared with women unexposed to the drug.⁷⁶ The data are preliminary and need confirmation, but further support the belief that the uterine cervix is an endocrine target organ whose neoplastic potential may depend on hormonal influences.

OTHER GYNECOLOGIC CANCERS AND EXOGENOUS SEX STEROIDS

The causal relationship between DES exposure in utero and the subsequent occurrence of *clear cell carcinomas of the vagina and cervix* is well established. This relationship was first observed in the early 1970s and, subsequently, a registry was established that accumulated over 400 cases of this malignancy in women born after 1940.⁷⁷ Estimates of the risk of this malignancy among those exposed to the drug are about 1:10,000. In almost all documented cases, the treatment with DES had started before the 18th week of pregnancy, and there is evidence that the earlier in pregnancy the treatment was initiated, the greater the risk. Dose- and duration-response relationships remain somewhat less clear.

An interesting feature of this malignancy is the attack rate by age. The patients seem to be diagnosed primarily from preadolescence through 30 years of age. The slope of the attack rate curve is particularly steep from 11 through 20 years of age. This implies that the onset of puberty is required for expression of the carcinogenic effect and may indicate a promotional role for endogenous hormones in completing the carcinogenic effect of DES.

Several studies have linked long-term use of oral contraceptives to increased risk of *trophoblastic disease* (see Chaps. 109 and 110), whereas others have suggested that such use may increase the risk of malignant sequelae after mole evacuation. However, several other investigations⁷⁸ have failed to find these effects, leaving this as an important area for future investigations designed to address these differences.

MALE GENITAL CANCERS AND SEX STEROIDS

The roles of sex hormones in male genital cancers have not been well studied, but there is substantial reason to believe that hormonal factors do operate.

Because of its relative rarity, *testicular cancer* has not often been the subject of major analytic epidemiologic investigations (see Chap. 122). Studies of testicular cancer in relatively young men, and other studies of cryptorchidism (a major risk factor for this tumor), have implied that high levels of circulating estrogens (from either an endogenous or exogenous source) in a pregnant woman could place a male offspring exposed in utero at a high subsequent risk of these conditions.⁷⁹ These preliminary findings indicate the need for attention to hormonal risk factors for testicular cancer.

Although *prostate cancer* is a common malignancy among men in the United States, little is known with certainty about its etiology in humans. Many investigators hypothesize a hormonal influence based on the roles of sex hormones in the development and maintenance of normal prostatic function, experimental evidence, the responsiveness of prostatic cancer to therapeutic hormonal manipulation, and limited clinical data. It also has been speculated that some of the descriptive risk factors for this disease, including racial and ethnic variation, may operate through a hormonal mechanism. Prominent hormonal hypotheses^{80,81} suggest an increased risk of prostatic cancer caused by increased levels of testosterone, decreased levels of estrogen, increased levels of prolactin, differential activity of 5 α -reductase, or some combination of these. Despite the frequency of the malignancy and the concerns over a hormonal etiology, few epidemiologic data exist to address these hypotheses. This lack of analytic studies stems partly from doubts that hormonal patterns in patients with prostatic cancer accurately reflect the premorbid patterns, and partly from the technical difficulties in assaying for the particular hormones of primary interest.

LIVER CANCER AND SEX STEROIDS

Hormones have been linked to liver tumors in men and women. The androgenic-anabolic steroids and the oral contraceptives have been implicated.

ANDROGENIC-ANABOLIC STEROIDS AND LIVER CANCER

Androgenic-anabolic steroids in the form of oxymetholone or methyltestosterone derivatives were first linked to hepatocellular carcinoma by case reports⁸² of patients undergoing long-term therapy for aplastic anemia. Patients with Fanconi anemia seemed to be at special risk, consistent with their heritable predisposition to acute leukemia and other cancers.⁸³ Liver tumors also have occurred when the steroids were used for conditions

other than aplastic anemia, and some tumors have regressed on drug withdrawal. Although these findings are provocative, they are difficult to interpret because other risk factors for primary liver cancer, particularly the presence of hepatitis B virus, have not been evaluated in these studies, and they may be more common in these conditions. Resolution of these methodologic concerns was not important until the abuse of these androgenic drugs by body builders and other athletes became common (see Chap. 119).

ORAL CONTRACEPTIVES AND BENIGN LIVER TUMORS

A number of clinical reports⁸⁴ describing young women receiving oral contraceptives who developed benign liver tumors have appeared in the literature. These tumors were highly vascular and often presented as emergencies with abdominal hemorrhage and shock. Two analytic case-control studies^{85,86} have linked these tumors to the use of oral contraceptives. The risk for users of 3 to 5 years was about 100 times that of nonusers, and the risk for users of 7 or more years about 500 times that of nonusers. The risks also appear to be higher for users older than 30 years of age, and for users of relatively high-potency pills. Although the RR is high, the absolute risk is not large for this rare tumor. The risk of hepatocellular adenoma among women younger than 30 years of age may be no more than 3:100,000 contraceptive users per year. Over this age the absolute risk probably is greater but not precisely estimated.

ORAL CONTRACEPTIVES AND LIVER CANCER

Because of the findings of these benign tumors and the role of the liver in metabolizing steroid hormones, much concern has been expressed over the potential for a relationship between oral contraceptive use and the risk of malignant liver tumors. Thus, the reports of a duration-related excess risk of this tumor with oral contraceptive use from six case-control investigations in the 1980s was further cause for substantial concern. The overall excesses were around 2.5-fold for "ever" users and over ninefold for long-term users.⁸⁷ All of these reports were from countries with low incidence rates of primary liver cancer and the numbers of cases in each study were limited, ranging from 12 to 26 patients. A study⁸⁸ in the United States, including 76 women who died of this tumor, has confirmed these excess risks. Two investigations^{89,90} in high-risk countries have not noted an excess risk with contraceptive use, but in each instance the numbers of long-term users were few.

OTHER TUMORS

For some time, there has been speculation that endogenous hormones, particularly estrogens, might figure in the etiology of malignant melanoma. One follow-up study and one case-control study^{91,92} conducted in the late 1970s implied that oral contraceptive users may be at 50% to 80% increased risk for this tumor. Partially because of the marked rise in incidence of malignant melanoma during the 1960s and 1970s, this finding caused considerable concern. Critical reviews noted the equally impressive rise in the incidence of skin melanoma among men, and that the two positive studies had not obtained information on other possible risk factors that might be related to oral contraceptive use, particularly the duration of exposure to sunlight. Several investigations were launched to assess this issue. Although the results have been mixed, the level of concern has declined.

Also, in the late 1970s, a number of clinical series of cases of pituitary adenoma were reported among young women, a high proportion of whom had recently stopped using oral contraceptives. Subsequent investigations⁹³ have indicated that this association probably was not causal, but reflected the increased use

of computed tomography in detection of pituitary abnormalities among women with postcontraceptive menstrual disorders.

A number of other tumors have been suggested as being related to sex hormone levels because of a higher rate among women than men, a relationship to reproductive characteristics, or isolated observations of altered frequency among exogenous hormone users. In this category are cancers of the *gallbladder, thyroid, kidney, colon, and lung*. Most of the observations concerning these sites remain preliminary and speculative, but clearly mark these tumors as candidates for more analytical assessments in the future.

REFERENCES

1. International Agency for Research on Cancer. Evaluation of the carcinogenic risk of chemicals to man. In: Sex hormones, ed 2, vol 21. Lyon, France: IARC, 1979:11.
2. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Rubard and Hinda Rosenthal Foundation Award Lecture. *Cancer Res* 1988;48:246.
3. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. *N Engl J Med* 1980;303:1195.
4. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. *N Engl J Med* 1985;313:1044.
5. MacMahon B. Risk factors for endometrial cancer. *Gynecol Oncol* 1974;2:122.
6. Armstrong BK. The role of diet in human carcinogenesis with special reference to endometrial cancer. In: Watson JD, Hiatt HH, Winsten JA, eds. *Origins of human cancer*. New York: Cold Spring Harbor Laboratory, 1977:557.
7. Brinton LA. The relationship of exogenous estrogens to cancer risk. *Cancer Detect Prev* 1984;7:159.
8. Ziel HK, Finkle WD. Increased risk of endometrial cancer among users of conjugated estrogens. *N Engl J Med* 1975;293:1167.
9. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. *N Engl J Med* 1976;294:1262.
10. Gray LA Sr, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. *Am J Obstet Gynecol* 1977;49:385.
11. Antunes CMF, Stolley PO, Rosenshein NB, et al. Endometrial cancer and estrogen use: report of a large case-control study. *N Engl J Med* 1979;300:9.
12. Weiss NS, Szekely DR, English DR, Schwind AI. Endometrial cancer in relation to patterns of menopausal estrogen use. *JAMA* 1979;242:261.
13. Hulka BS, Fowler WC Jr, Kaufman DG, et al. Estrogen and endometrial cancer: cases and two control groups from North Carolina. *Am J Obstet Gynecol* 1980;137:92.
14. Shapiro S, Kaufman DW, Slone D, et al. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. *N Engl J Med* 1980;303:485.
15. Brinton LA, Hoover RN, et al. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. *Obstet Gynecol* 1993;81:265.
16. Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of estrogen and progestins on the biochemistry and morphology of the postmenopausal endometrium. *N Engl J Med* 1981;305:1599.
17. Persson I, Adami H-O, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: results of a prospective study. *Br Med J* 1989;298:147.
18. Voight LF, Weiss NS, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. *Lancet* 1991;308:274.
19. Silverberg SG, Makowski EL. Endometrial carcinoma in young women taking oral contraceptive agents. *Obstet Gynecol* 1975;46:503.
20. Weiss NS, Sayvitz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. *N Engl J Med* 1980;302:551.
21. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. *N Engl J Med* 1980;303:1045.
22. Hulka BS, Chambless LE, Kaufman DG, et al. Protection against endometrial carcinoma by combination-product oral contraceptives. *JAMA* 1982;247:475.
23. Henderson BE, Casagrande JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. *Br J Cancer* 1983;47:749.
24. The Centers for Disease Control Cancer and Steroid Hormone Study. Oral contraceptive use and the risk of endometrial cancer. *JAMA* 1983;249:1600.
25. Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? *Int J Cancer* 1993;54:243.
26. Gangemi M, Meneghetti G, Dredebou O, et al. Obesity as a risk factor for endometrial cancer. *Clin Exp Obstet Gynecol* 1987;14:119.
27. Hoover RN. Hormonal, infectious, and nutritional aspects of cancer of the female reproductive tract. In: Harris CC, ed. *Biochemical and molecular epidemiology of cancer*. New York: Alan R Liss, 1985:313.
28. MacMahon B, Cole P. The ovarian etiology of human breast cancer. *Recent Results Cancer Res* 1972;39:185.
29. MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. *J Natl Cancer Inst* 1973;50:21.

30. Tulinius H, Day NE, Johansson G, et al. Reproductive factors and risk for breast cancer in Iceland. *Int J Cancer* 1978; 21:724.
31. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med* 1985; 312:146.
32. London SJ, Coldite GA, Stampfer MJ, et al. A prospective study of relative weight, height, and risk of breast cancer. *JAMA* 1984; 262:2853.
33. Schatzkin A, Greenwald P, Byar DP, Clifford CK. The dietary fat-breast cancer hypothesis is alive. *JAMA* 1989; 261:3284.
34. Phillips RL, Garfinkel L, Kuzona JW, et al. Mortality among California Seventh-Day-Adventists for selected cancer sites. *J Natl Cancer Inst* 1980; 65:1097.
35. Kinlen LJ. Meat and fat consumption and cancer mortality: a study of strict religious orders in Britain. *Lancet* 1982; 1:946.
36. Willett WC, Stampfer M-T, Colditz GA, et al. Dietary fat and the risk of breast cancer. *N Engl J Med* 1987; 316:22.
37. Jones DY, Schatzkin A, Green SB, et al. Dietary fat and breast cancer in the National Health and Nutrition Examination Survey I epidemiologic follow-up study. *J Natl Cancer Inst* 1987; 79:465.
38. England PC, Skinner LG, Cottrell KM, Sellwood RA. Serum oestradiol-17 β in women with benign and malignant breast disease. *Br J Cancer* 1974; 30:571.
39. Key TA, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. *Eur J Cancer* 1988; 24:29.
40. Sherman BM, Korenman SG. Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology. *Cancer* 1974; 33:1306.
41. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. *Lancet* 1969; 1:604.
42. Korenman SG. Oestrogen window hypothesis of the aetiology of breast cancer. *Lancet* 1980; 1:700.
43. Reed MJ, Beranek PA, Cheng RW, et al. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. *Int J Cancer* 1985; 35:457.
44. Musey V, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. *N Engl J Med* 1987; 316:229.
45. Hoover RN, Gray LA, Cole P, MacMahon B. Menopausal estrogens and breast cancer. *N Engl J Med* 1976; 295:401.
46. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. *JAMA* 1980; 243:1635.
47. Hoover R, Glass A, Finkle WD, et al. Conjugated estrogens and breast cancer risk in women. *J Natl Cancer Inst* 1981; 67:815.
48. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal estrogen and breast cancer risk: an expanded case-control study. *Br J Cancer* 1986; 54:825-832.
49. Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy. *Am J Obstet Gynecol* 1982; 143:638.
50. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. *Cancer* 1984; 54:139.
51. Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. *J Natl Cancer Inst* 1981; 67:327.
52. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. *JAMA* 1984; 252:63.
53. Thomas DB, Persing JP, Hutchinson WB. Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases. *J Natl Cancer Inst* 1982; 69:1017.
54. Wingo PA, Layde PM, Lee NC, et al. The risk of breast cancer in postmenopausal women who have used estrogen. *JAMA* 1987; 257:209.
55. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. *Br J Obstet Gynecol* 1987; 94:620.
56. Bergkvist L, Adami H-O, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. *N Engl J Med* 1989; 321:293.
57. Steinberg KK, Thacker SB, Smith SJ. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. *JAMA* 1991; 265:1985.
58. DES Task Force. Report of the 1985 DES Task Force. Bethesda, MD, National Cancer Institute, 1985:1.
59. Pike MC, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation at age of use. *Lancet* 1983; 2:926.
60. McPherson K, Neil A, Vessey MP, Doll R. Oral contraceptives and breast cancer. *Lancet* 1983; 2:1414.
61. Meirik O, Lund E, Adami H-O, et al. Oral contraceptive use and breast cancer in young women. *Lancet* 1986; 2:650.
62. Paul C, Shegg DCG, Spears DGS. Oral contraceptives and risk of breast cancer. *Int J Cancer* 1990; 46:366.
63. White E, Malone KE, Weiss NS, et al. Breast cancer among young U.S. women in relation to oral contraceptive use. *J Natl Cancer Inst* 1994; 86:505.
64. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. *Lancet* 1989; 2:973.
65. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. *Semin Oncol* 1984; 11:209.
66. Hoover R, Gray LA Sr, Fraumeni JF Jr. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. *Lancet* 1977; 1:533.
67. Whittemore AS, Harris R, Itytre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. *Am J Epidemiol* 1992; 136:1184.
68. Brinton LA, Fraumeni JF Jr. Epidemiology of uterine cervical cancer. *J Chronic Dis* 1986; 39:1051.
69. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. *J Natl Cancer Inst* 1993; 85:958.
70. Brinton LA, Schairer C, Haenszel W, et al. Cigarette smoking and invasive cervical cancer. *JAMA* 1986; 255:3265.
71. Brinton LA, Reeves WC, Brenes MM, et al. Parity as a risk factor for cervical cancer. *Am J Epidemiol* 1989; 130:486.
72. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Invasive cervical cancer and combined oral contraceptives. *Br Med J* 1985; 290:961.
73. Brinton LA, Huggins GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. *Int J Cancer* 1986; 38:339.
74. Bosch FX, Munoz N, DeSanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. *Int J Cancer* 1992; 52:750.
75. Eluf-Neto J, Booth M, Munoz N. Human papillomavirus and invasive cervical cancer in Brazil. *Br J Cancer* 1994; 69:114.
76. Robboy SJ, Noller KL, O'Brien P, et al. Increased incidence of cervical and vaginal dysplasia in 3980 diethylstilbestrol-exposed young women. *JAMA* 1984; 252:2979.
77. Herbst AL. Clear cell adenocarcinoma and the current status of DES-exposed females. *Cancer* 1981; 48:484.
78. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: JB Lippincott, 1992:3.
79. Depue RH. Maternal and gestational factors affecting the risk of cryptorchidism and inguinal hernia. *Int J Epidemiol* 1984; 13:311.
80. Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. *Lancet* 1992; 339:887.
81. Flanders WD. Review: prostate cancer epidemiology. *Prostate* 1984; 5:621.
82. Hoover R, Fraumeni JF Jr. Drug-induced cancer. *Cancer* 1981; 47:1071.
83. Okuyama S, Mishina H. Fanconi's anemia as nature's evolutionary experiment on carcinogenesis. *Tohoku J Exp Med* 1987; 153:87.
84. Baum JK, Holtz F, Bookstein JJ, Klein EW. Possible association between benign hepatomas and oral contraceptives. *Lancet* 1973; 2:926.
85. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with the use of oral contraceptives. *N Engl J Med* 1976; 294:470.
86. Rooks JB, Ory HW, Ishak KC, et al. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. *JAMA* 1979; 242:644.
87. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. *Prev Med* 1991; 20:38.
88. Hsing AW, Hoover RN, McLaughlin JK. Oral contraceptives and primary liver cancers among young women. *Cancer Causes Control* 1992; 3:43.
89. WHO Collaborative Study of Neoplasia and Steroid contraceptives. Combined oral contraceptives and liver cancer. *Int J Cancer* 1989; 43:254.
90. Kew MC, Song E, Mohammed A, Hodgkinson J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case/control study in South African black women. *Hepatology* 1990; 11:298.
91. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. *Br J Cancer* 1977; 36:804.
92. Holman CDJ, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. *Br J Cancer* 1984; 50:673.
93. Pituitary Adenoma Study Group. Pituitary adenomas and oral contraceptives: a multicenter case-control study. *Fertil Steril* 1983; 39:752.